AWARD OUTCOME
What happened
The Clatterbridge Cancer Centre NHS Foundation Trust published a transparency notice for a direct award to Bristol-Myers Squibb Pharmaceuticals Limited for Breyanzi CAR POS T-Cells. The source describes the award as pending, with a future signature date scheduled for 8 October 2026.
Published outcomePending direct award to Bristol-Myers Squibb Pharmaceuticals Limited for lot 1, valued at £140,250 gross.
Market significanceA single-supplier pharmaceutical procurement commissioned via NHS England, covering a short stated delivery/contract period.
AWARDED SUPPLIERS AND LOTS
1 supplier record analysed
BRISTOL-MYERS SQUIBB PHARMACEUTICALS LIMITED
99% confidenceAward 1 · Lots 1 · 140250 GBP · Pending award
View supporting evidence
Award 1 names BRISTOL-MYERS SQUIBB PHARMACEUTICALS LIMITED as supplier, covers related lot 1, has status pending and value £140,250.
LIFECYCLE
Award or contract stage
Notice status
95% confidencePublished transparency notice; tender status complete
View supporting evidence
Process display status is awarded; notice type is Transparency notice on Find a Tender; tender status is complete.
Award status
99% confidencePending
View supporting evidence
Award 1 has status 'pending'.
Signature status
98% confidenceFuture signature scheduled, not evidenced as completed
View supporting evidence
Award milestone is futureSignatureDate due 2026-10-08T23:59:59+01:00 with status scheduled.
VALUES
Published values explained
Award value
99% confidence£140,250 gross
View supporting evidence
Award 1 value states amountGross 140250, amount 140250, currency GBP.
Value allocation
95% confidenceAward-level value for one named supplier and lot 1
View supporting evidence
Award 1 identifies one supplier and related lot 1.
TIMELINE
Procurement timeline
Transparency notice published
99% confidence8 October 2026
View supporting evidence
Award notice document datePublished is 2026-10-08T07:55:13+01:00.
Stated contract period start
98% confidence8 October 2026
View supporting evidence
Award 1 contractPeriod startDate is 2026-10-08T00:00:00+01:00.
Scheduled signature deadline
98% confidence8 October 2026
View supporting evidence
Future signature milestone dueDate is 2026-10-08T23:59:59+01:00.
Stated contract period end
98% confidence9 October 2026
View supporting evidence
Award 1 contractPeriod endDate is 2026-10-09T23:59:59+01:00.
SCOPE
What was awarded
Requirement
99% confidencePurchase of Breyanzi CAR POS T-Cells, supplied direct and commissioned via NHS England
View supporting evidence
Tender title and description state this requirement.
Procurement category
99% confidenceGoods
View supporting evidence
Award 1 mainProcurementCategory is goods.
Classification
99% confidenceCPV 33600000 — Pharmaceutical products
View supporting evidence
Award item additional classification is CPV 33600000, Pharmaceutical products.
Delivery region
95% confidenceUKD72, United Kingdom
View supporting evidence
Award item delivery address specifies region UKD72 and country GB.
PROCEDURE
Procedure and competition
Procurement method
99% confidenceDirect award
View supporting evidence
Tender procurementMethod is direct and procurementMethodDetails is Direct award.
Published rationale
99% confidenceCommissioned by NHS England and single supplier only for this service
View supporting evidence
Tender procurementMethodRationale contains this wording.
Rationale classification
98% confidenceSingle supplier for technical reasons
View supporting evidence
procurementMethodRationaleClassifications includes singleSuppliersTechnicalReasons.
Competition information
99% confidenceNo bid count or evaluation information supplied
View supporting evidence
The published source contains no bidder count, scoring or evaluation details.
CONTRACT TERMS
Published contract terms
Stated period
98% confidence8 October 2026 to 9 October 2026
View supporting evidence
Award 1 contractPeriod specifies these dates.
Contract conclusion
99% confidenceNot evidenced as signed or concluded
View supporting evidence
The award is pending and its signature milestone is scheduled rather than completed.
Extensions or options
99% confidenceUnknown
View supporting evidence
Information not supplied in the published notice.
COMMERCIAL VIEW
Commercial observations
Supply route
98% confidenceDirect supply arrangement
View supporting evidence
Tender description says products are to be supplied direct.
Market structure signal
98% confidenceThe buyer reports a single supplier for this service
View supporting evidence
Published direct-award rationale states 'single supplier only for this service'.
Commercial timing
95% confidenceThe stated period is two calendar days, subject to pending award and scheduled signature status
View supporting evidence
Contract period runs from 8 to 9 October 2026; award remains pending.
DATA QUALITY
Gaps and source limitations
Award-record inconsistency
99% confidenceA secondary award record lists award ID 2 as active, but the detailed notice contains only award ID 1, which is pending.
View supporting evidence
Top-level awards includes ID 2 active; tender awards array contains only ID 1 pending.
Lot detail
99% confidenceLot 1 has no published title, description or separate value.
View supporting evidence
Lot record contains null title, description and value.
Evaluation and competition data
99% confidenceInformation not supplied in the published notice.
View supporting evidence
No bid count, tender submissions, scores or evaluation narrative is present.
Conflict-of-interest document
99% confidenceNot published
View supporting evidence
Tender documents include conflictOfInterest with description 'Not published'.
SOURCE DATA LIMITATIONS
Information not supplied in the published notice
- No award decision date is published.
- No evidence of completed signature or contract conclusion is published.
- No tender submission deadline is published.
- No bid count, evaluation scores, pricing breakdown or award-decision narrative is published.
- Lot 1 title, description and standalone value are not published.
- No extension, option or renewal terms are published.
MARKET THEMES
Relevant award themes
Breyanzi CAR POS T-CellsClatterbridge Cancer CentreBristol-Myers Squibb Pharmaceuticalsdirect awardpharmaceutical productsNHS England
COMMON QUESTIONS
About this award
Who is named as supplier?
Bristol-Myers Squibb Pharmaceuticals Limited is named for award 1 and lot 1.
Has the contract been signed?
The published award is pending and shows a signature date as scheduled; signing is not evidenced.
Why was a direct award used?
The published rationale says the requirement was commissioned by NHS England and had a single supplier for the service.
ProcuraAxis award analysis supplements, but does not replace, the official award notice, contract data or procurement documents. “Awarded” does not by itself prove that a contract has been signed.